Torray Investment Partners LLC Sells 3,786 Shares of Krystal Biotech, Inc. $KRYS

Torray Investment Partners LLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 31.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,370 shares of the company’s stock after selling 3,786 shares during the period. Torray Investment Partners LLC’s holdings in Krystal Biotech were worth $2,784,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Bridge City Capital LLC grew its holdings in shares of Krystal Biotech by 21.9% during the third quarter. Bridge City Capital LLC now owns 14,404 shares of the company’s stock valued at $4,790,000 after buying an additional 2,588 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Krystal Biotech in the 3rd quarter worth $503,000. Profund Advisors LLC raised its stake in Krystal Biotech by 26.7% in the 3rd quarter. Profund Advisors LLC now owns 7,313 shares of the company’s stock worth $2,432,000 after acquiring an additional 1,543 shares during the last quarter. ProShare Advisors LLC lifted its position in Krystal Biotech by 13.1% during the 3rd quarter. ProShare Advisors LLC now owns 5,385 shares of the company’s stock worth $1,791,000 after acquiring an additional 625 shares during the period. Finally, Vise Technologies Inc. lifted its position in Krystal Biotech by 25.7% during the 3rd quarter. Vise Technologies Inc. now owns 2,214 shares of the company’s stock worth $736,000 after acquiring an additional 452 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Royal Bank Of Canada dropped their price target on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a research note on Tuesday. Bank of America lifted their target price on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group assumed coverage on Krystal Biotech in a research report on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $361.00 price target on shares of Krystal Biotech in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and an average price target of $375.00.

Krystal Biotech Stock Up 3.1%

Shares of KRYS stock opened at $305.03 on Wednesday. Krystal Biotech, Inc. has a 52-week low of $192.52 and a 52-week high of $382.54. The stock has a market cap of $9.03 billion, a PE ratio of 40.15 and a beta of 0.56. The business has a 50-day simple moving average of $335.72 and a 200-day simple moving average of $308.77.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.79 by $0.26. The firm had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.33 earnings per share for the current fiscal year.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Third-quarter EPS was $2.05, above estimates, while revenue of $127.34 million also topped forecasts and grew about 30% year over year. Vyjuvek strength supported the results. Krystal Biotech Q3 results
• Positive Sentiment: The company announced a $400 million share-repurchase program over two years, which may support demand for the shares. Share repurchase announcement
• Neutral Sentiment: Citigroup, TD Cowen and RBC lowered their price targets, but continued to rate KRYS Buy or Outperform, indicating continued optimism alongside more cautious valuation assumptions. RBC assessment
• Negative Sentiment: Pipeline timelines have slipped into 2027, delaying potential development milestones. Quarterly EPS also declined from $2.66 a year earlier, despite beating analyst estimates, contributing to a cautious reaction to the earnings news. Results and pipeline update

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.